SPR Therapeutics Revenue and Competitors

Location

#718

Growjo Ranking

Estimated Revenue & Valuation

  • SPR Therapeutics's estimated annual revenue is currently $108.9M per year.(i)
  • SPR Therapeutics received $25.0M in venture funding in September 2017.
  • SPR Therapeutics's estimated revenue per employee is $351,400
  • SPR Therapeutics's total funding is $174M.

Employee Data

  • SPR Therapeutics has 310 Employees.(i)
  • SPR Therapeutics grew their employee count by 17% last year.

SPR Therapeutics's People

NameTitleEmail/Phone
1
Chief EngineerReveal Email/Phone
2
ControllerReveal Email/Phone
3
SVP, Market DevelopmentReveal Email/Phone
4
SVP, SalesReveal Email/Phone
5
VP MarketingReveal Email/Phone
6
VP, Regulatory, Quality, & New Product Development; Compliance OfficerReveal Email/Phone
7
Chief Financial OfficerReveal Email/Phone
8
Director Market AccessReveal Email/Phone
9
Director Human ResourcesReveal Email/Phone
10
Director Training and Patient SupportReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$470.6M18751%N/AN/A
#2
$16.3M65-2%N/AN/A
#3
$7.8M310%N/AN/A
#4
$3.8M150%N/AN/A
#5
$21.1M844%N/AN/A
#6
$70M2798%N/AN/A
#7
$4M16-11%N/AN/A
#8
$135.3M5390%N/AN/A
#9
$11.5M465%N/AN/A
#10
$8.8M3535%N/AN/A
Add Company

What Is SPR Therapeutics?

SPR Therapeutics is committed to improving the lives of millions of pain sufferers with its peripheral nerve stimulation (PNS) platform technology poised to be the standard of care and ultimately, the treatment of choice for pain management. Led by a world-class team of scientists, physicians, and business professionals with a track record of commercializing innovative neurostimulation products, SPR's PNS therapy for acute and chronic pain management provides a non-narcotic, reversible, safe, effective and more affordable alternative to addictive opioid medications and invasive surgeries.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$174M

Total Funding

310

Number of Employees

$108.9M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SPR Therapeutics News

2022-03-30 - Global Pain Management Devices Market is expected to grow ...

In October 2021, SPR Therapeutics secured $37M VP funding to scale operations for Sprint pain relief device; In August 2020,...

2022-03-22 - SPR Therapeutics growing faster than expected because of ...

SPR Therapeutics Inc. used corporate shutdowns during the pandemic to educate potential users about its pain-relieving medical device,...

2021-10-18 - SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System

– Expanding U.S. Commercial Team Amid Record-Breaking Growth – CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has raised $37 million in an oversubscribe ...

2021-10-18 - SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System

CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has raised $37 million in an oversubscribed Series D growth equity financing. The investment will be used ...

2019-09-08 - Sacral Nerve Stimulation (SNS) Market growing by Increasing Market Share and Forecast 2026 with Top Key Players: Medtronic, LABORIE, Stimwave LLC, SunMed, Vygon SA

Medtronic; LABORIE; Stimwave LLC; SunMed; Vygon SA; Medline Industries, Inc.; NeuroMetrix, Inc.; SPR Therapeutics; NeuroSigma, Inc.; ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M3148%N/A
#2
$35M3146%N/A
#3
$300M318N/AN/A
#4
$125.4M3297%N/A
#5
$111.4M3307%N/A

SPR Therapeutics Funding

DateAmountRoundLead InvestorsReference
2011-04-27$0.2MUndisclosedJumpStart VenturesArticle
2012-01-25$2.2MANDI MedicalArticle
2013-01-09$5.0MANDI Healthcare Fund, Public Square PartnersArticle
2014-06-12$3.9MUndisclosedArticle
2017-09-13$25.0MCArticle